Compare Rivian Automotive, Inc. (RIVN) vs Tango Therapeutics Inc. (TNGX) Price & Performance

Rivian (RIVN) trades at $13.37, down 1.26% as investors react to mixed Q3 2026 delivery results. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal improving revenue trends ($5.39B in 2025) but persistent losses (-$3.65B net income). Recent news highlights record vehicle deliveries of 19,248 units in Q3 2026 but disappointment over unchanged full-year guidance.

The outlook remains challenging with significant cash burn and negative margins, though analyst consensus suggests 26% upside to the $16.89 price target. Key risks include execution on R2 production ramp, competitive EV market pressures, and path to profitability. The stock trades near analyst low targets, reflecting cautious optimism about Rivian's scaling potential.

TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.

Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.